Form 6-K — CureVac N.V.: financial results for the third quarter and nine months of 2021 (November 18, 2021)

Summary

A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of November, 2021, Commission File Number 001-39446. It states that on November 18, 2021 the company issued a press release announcing its financial results and business updates for the third quarter and first nine months of 2021. The information is incorporated by reference into a Form F-3 registration statement, File No. 333-259613, except for statements of the Chief Executive Officer and Chief Financial Officer in the exhibit. The press release is listed as Exhibit 99.1.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE
ISSUER

PURSUANT TO RULE 13a-16
OR 15d-16 OF THE

SECURITIES EXCHANGE ACT
OF 1934

For the month of November, 2021

Commission File Number: 001-39446

CureVac N.V.

( Exact Name of Registrant as Specified in Its
Charter )

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F | x | Form 40-F | ¨

Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes | ¨ | No | x

Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes | ¨ | No | x

On November 18, 2021, CureVac N.V. (the “Company”) issued
a press release announcing the Company’s financial results and business updates for the third quarter and first nine months of 2021.

The information included in this Form 6-K (including Exhibit 99.1,
but excluding the statements of CureVac N.V.’s Chief Executive Officer and Chief Financial Officer contained in Exhibits 99.1
thereto) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CUREVAC N.V.
By: | /s/ Franz-Werner Haas, LLD, LLM
Chief Executive Officer

Date: November 18, 2021

EXHIBIT INDEX

EXHIBIT NO. | DESCRIPTION
99.1 | CureVac N.V. Press Release dated November 18, 2021.

File and source

File

SEC_CVAC_6-K_filed2021-11-18_0001104659-21-141202.htm

Size

13,469 bytes

SHA-256

cb4f66846329edeb5d922e50a836a7dc1ff09a00cff577315ddbea045964db83

Our copy

SEC_CVAC_6-K_filed2021-11-18_0001104659-21-141202.htm

Original

www.sec.gov